Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-06-2010 | Focus on

Radiation exposure, protection and risk from nuclear medicine procedures

Authors: Massimo Salvatori, Giovanni Lucignani

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2010

Excerpt

“Primum non nocere” …

Mettler Jr FA, Bhargavan M, Faulkner K, Gilley DB, Gray JE, Ibbott GS, et al. Radiologic and nuclear medicine studies in the United States and worldwide: frequency, radiation dose, and comparison with other radiation sources—1950–2007. Radiology. 2009;253(2):520–31.CrossRefPubMed

Lucignani G. Radiation burden in myocardial imaging: an old concern in the new age of hi-tech, hybrid imaging. Eur J Nucl Med Mol Imaging. 2010;37(1):169–74.CrossRefPubMed

Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD Pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry—standardization of nomenclature. J Nucl Med. 2009;50(3):477–84.CrossRefPubMed

Sgouros G, Howell RW, Bolch WE, Fisher DR. MIRD commentary: proposed name for a dosimetry unit applicable to deterministic biological effects—the barendsen (Bd). J Nucl Med. 2009;50:485–7.CrossRefPubMed

Huang B, Law MW, Khong PL. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology. 2009;251(1):166–74.CrossRefPubMed

Fahey FH. Dosimetry of pediatric PET/CT. J Nucl Med. 2009;50:1483–91.CrossRefPubMed

Gelfand MJ. Dosimetry of FDG PET/CT and other molecular imaging applications in pediatric patients. Pediatr Radiol. 2009;39 Suppl 1:S46–56.CrossRefPubMed

Hosseinimehr SJ. Potential utility of radioprotective agents in the practice of nuclear medicine. Cancer Biother Radiopharm. 2009;24(6):723–31.CrossRefPubMed

Ma C, Xie J, Jiang Z, Wang G, Zuo S. Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010. doi: 10.1007/s00259-009-1368-6.

10.

Rolleman EJ, Melis M, Valkema R, Boerman OC, Krenning EP, de Jong M. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging. 2009 Nov 14. [Epub ahead of print].

11.

de Carvalho JW, Sapienza M, Ono C, Watanabe T, Guimarães MI, Gutterres R, et al. Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe? Nucl Med Commun. 2009;30(7):533–41.CrossRefPubMed

12.

de Carvalho AB, Jr HJ, Silva AX, Garcia FJ. Use of a voxel phantom as a source and a second voxel phantom as a target to calculate effective doses in individuals exposed to patients treated with 131I. J Nucl Med Technol. 2009;37(1):53–6.CrossRefPubMed

13.

Asli IN, Baharfard N, Shafiei B, Tabei F, Javadi H, Seyedabadi M, et al. Relation between clinical and laboratory parameters with radiation dose rates from patients receiving iodine-131 therapy for thyroid carcinoma. Radiat Prot Dosimetry. 2009 Nov 17 [Epub ahead of print].

14.

Stapel AG, van der Zant FM, Gommans GM, Boer RO, Reigman HI. The effects of a custom-made lead collar on dose rates of patients treated with 131I. Health Phys. 2009;96(5 Suppl 2):S64–8.CrossRefPubMed

15.

Watanabe H, Satou T, Senzui N, Kimura F, Sano M, Hoshi T, et al. National survey of radiation protection for workers in positron emission tomography facilities in Japan-1st report: occupational role assignment, radiation exposure to medical workers. Nippon Hoshasen Gijutsu Gakkai Zasshi. 2009;65(3):285–94.PubMed

16.

Kristoffersen US, Gutte H, Skovgaard D, Andersen PA, Kjaer A. Radiation exposure for medical staff performing quantitative coronary perfusion PET with 13N-ammonia. Radiat Prot Dosim. 2010;138(2):107–10.CrossRef

17.

Calandrino R, del Vecchio A, Savi A, Todde S, Belloli S. Intake risk and dose evaluation methods for workers in radiochemistry labs of a medical cyclotron facility. Health Phys. 2009;97(4):315–21.CrossRefPubMed

18.

Grassi E, Sghedonia R, Asti M, Fioroni F, Salvo D, Borasi G. Radiation protection in 90Y-labelled DOTA-D-Phe1-Tyr3-octreotide preparations. Nucl Med Commun. 2009;30(12):176–82.CrossRefPubMed

19.

Jødal L. Beta emitters and radiation protection. Acta Oncol. 2009;48(2):308–13.CrossRefPubMed

20.

Freudenberg LS, Müller SP, Bockis A. Subjective perceptions of patients undergoing radioiodine therapy: why should we know about them? Eur J Nucl Med Mol Imaging. 2009;36(11):1743–4.CrossRefPubMed

Title: Radiation exposure, protection and risk from nuclear medicine procedures
Authors: Massimo Salvatori
Giovanni Lucignani
Publication date: 01-06-2010
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2010
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-010-1474-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Radiation exposure, protection and risk from nuclear medicine procedures

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2010

Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging

Measurement of coronary flow reserve by noninvasive cardiac imaging

EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry

The effect of anaesthesia on [18F]MK-9470 binding to the type 1 cannabinoid receptor in the rat brain

Erratum to: Guidelines for the labelling of leucocytes with 111In-oxine

PSA doubling time for prediction of [11C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy